| 证券代码：605116 | 证券简称：奥锐特 | 公告编号：2025-040 | | --- | --- | --- | | 债券代码：111021 | 债券简称：奥锐转债 | | 奥锐特药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/22 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 6,000万元~12,000万元 | | 回购用途 | □减少注册资本 □用于员工持股计划或股权激励 | | | √用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 136.09万股 | | 累计已回购股数占总股本比例 | 0.34% | | 累计已回购金额 | 27,090,786.00 元 | | 实际回购价格区间 | 18.83元/股~21.00元/股 | 一、回购股份的基本情况 2025 年 1 月 21 ...

证券代码：605116 证券简称：奥锐特 公告编号：2025-039 债券代码：111021 债券简称：奥锐转债 （一）本次担保基本情况 2025年5月26日，公司与招商银行股份有限公司扬州分行（以下简称"招商 银行"）签署了《最高额不可撤销担保书》(编号：2025年最保字第210500281 号)，同意公司为全资子公司扬州奥锐特向招商银行申请的《授信协议》（编号： 2025年授字第210500281号，授信期间为2025年5月26日至2026年5月25日）提供 连带保证责任，担保总额为人民币4,000万元。本次担保未提供反担保。 （二）本次担保事项履行的内部决策程序 奥锐特药业股份有限公司 关于为全资子公司提供担保进展情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本次担保情况概述 三、担保协议的主要内容 2025年4月24日，公司第三届董事会第十三次会议审议通过了《关于对外担 保额度预计的议案》。具体内容详见公司于2025年4月26日在上海证券交易所网 被担保人名称：公司全资子公司扬州奥锐特 ...

债券简称：奥锐转债 债券代码：111021 股票简称：奥锐特 股票代码：605116 第二次临时受托管理事务报告 （2025 年度） 受托管理人 二〇二五年五月 1 国泰海通证券股份有限公司 关于 奥锐特药业股份有限公司 向不特定对象发行可转换公司债券 重要声明 国泰海通证券股份有限公司(以下简称"国泰海通")编制本报告的内容及 信息来源于奥锐特药业股份有限公司(以下简称"奥锐特"、"公司"或"发行人") 对外公布的公开信息披露文件以及发行人向国泰海通提供的资料。 国泰海通按照《公司债券受托管理人执业行为准则》等相关规定及与奥锐特 签订的《受托管理协议》约定编制本报告。 本次发行的可转债期限为自发行之日起六年,即 2024年 7 月 26 日至 2030 年7月25日。 本报告不构成对投资者进行或不进行某项行为的推荐意见,投资者应对相关 事宜做出独立判断,而不应将本报告中的任何内容据以作为国泰海通所作的承诺 或声明。请投资者独立征询专业机构意见,在任何情况下,投资者不能将本报告 作为投资行为依据。 国泰海通提请投资者及时关注发行人的信息披露文件,并已督促发行人及时 履行信息披露义务。 2 一、核准文件及核准规 ...

国浩律师（杭州）事务所 关于 奥锐特药业股份有限公司 2024 年年度股东大会 法律意见书 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 二零二五年五月 奥锐特药业股份有限公司 2024 年年度股东大会 奥锐特 2024 年年度股东大会法律意见书 国浩律师（杭州）事务所 法律意见书 国浩律师（杭州）事务所 关 于 政法规、规范性文件及《公司章程》的规定发表法律意见。在本法律意见书中， 本所律师仅对本次股东大会表决程序及表决结果的合法有效性发表意见，不对会 议所审议的议案内容和该等议案中所表述的事实或数据 ...

奥锐特药业股份有限公司 2024年年度股东大会决议公告 证券代码：605116 证券简称：奥锐特 公告编号：2025-038 债券代码：111021 债券简称：奥锐转债 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 16 日 (二)股东大会召开的地点：浙江省天台县八都工业园区隆兴路 1 号公司行政大楼 会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 111 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 320,413,000 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 79.1467 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，公司董事长彭志恩先生主持。本次会议以 现场和网络投票相结合 ...

Group 1: Industry Overview - The overall revenue growth rate for the pharmaceutical and biotechnology sector in Q1 2025 was -4.8%, with a net profit growth rate of -12.2%[3] - The raw material drug sector showed resilience with a revenue growth rate of -3.6% and a net profit growth rate of 10.5% in Q1 2025, benefiting from demand recovery and price stabilization[3] Group 2: Profitability and Financial Performance - In 2024, major raw material drug companies saw an increase in gross margin and net margin by 0.78 percentage points and 0.39 percentage points respectively, while Q1 2025 saw a decline in average gross margin and net margin by 0.64 percentage points and 1.87 percentage points respectively[5] - The average operating cash flow for major raw material drug companies reached 10.04 billion yuan in 2024, a 14.65% increase from 2023, indicating a positive trend[31] Group 3: Capital Expenditure Trends - Capital expenditure for major raw material drug companies in 2024 totaled 7.242 billion yuan, reflecting a year-over-year decrease of 4.12%[36] - The capital expenditure to depreciation ratio for the raw material drug sector decreased from 1.79 in 2023 to 1.27 in 2024, indicating ongoing capacity reduction and structural adjustments[36] Group 4: Investment Strategy - Investment recommendations focus on selecting raw material drug companies with strong growth attributes and stable competitive landscapes, particularly in bulk and specialty raw materials[44] - Companies like Guobang Pharmaceutical and Tianyu Co., Ltd. are highlighted for their favorable supply dynamics and demand recovery[44] Group 5: Risk Factors - Risks include intensified competition leading to suboptimal recovery in product prices and volumes, production safety incidents, and exchange rate fluctuations impacting profitability[47]

Meeting Overview - The annual general meeting of Aurite Pharmaceutical Co., Ltd. is scheduled for May 16, 2025, at 14:30 [1] - The meeting will be held at the company's administrative building in Taizhou, Zhejiang Province [1] - Shareholders can participate through both on-site and online voting [1][4] Agenda Items - The meeting will discuss the remuneration plans for the board of directors and senior management for 2025, as well as confirm the execution of 2024 remuneration [2][3] - The meeting will also address the remuneration plan for the supervisors for 2025 and confirm the execution of 2024 remuneration [2] Company Performance - In 2024, the company achieved a net profit of 355 million yuan, a year-on-year increase of 22.59% [9] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, was 351 million yuan, reflecting a growth of 34.25% compared to the previous year [9] - The total assets of the company reached 3.877 billion yuan, an increase of 50.60% from the beginning of the year [10] - The total liabilities amounted to 1.546 billion yuan, up 154.67% from the beginning of the year [10] Business Development - The company continues to focus on the research, production, and sales of specialty complex APIs and pharmaceutical intermediates, maintaining a competitive edge in the market [10] - Revenue from the API and intermediate business grew by 7.73% year-on-year, with improved gross margins [10] - The company has made significant progress in expanding its online sales channels, with notable growth in sales of its products [10][11] Research and Development - The company invested 146 million yuan in R&D during the reporting period, a 6.91% increase year-on-year [11] - A total of 45 projects are currently under research, covering small molecule APIs, peptides, and oligonucleotides [11] - The company has submitted 29 invention patent applications and received 13 new patent grants during the reporting period [12][13] Financial Management - The company successfully issued convertible bonds, which will support its development projects and enhance its product matrix [14] - The total planned investment for the projects funded by the convertible bonds is approximately 1.020 billion yuan [14] Governance and Compliance - The board of directors held seven meetings during the year, ensuring compliance with legal and regulatory requirements [16][21] - The supervisory board conducted six meetings, focusing on financial oversight and compliance with corporate governance standards [25][29] Future Plans - The company aims to enhance its product offerings and expand its market presence, particularly in the fields of oligonucleotide and peptide drugs [24] - Plans include the construction of new production lines and the continuous improvement of its governance and management systems [24][25]

会议资料 2025 年 5 月 奥锐特药业股份有限公司 2024 年年度股东大会 奥锐特药业股份有限公司 2024 年年度股东大会会议资料 奥锐特药业股份有限公司 2024 年年度股东大会会议议程 一、会议时间 现场会议：2025 年 5 月 16 日（星期五）下午 14：30 网络投票：2025 年 5 月 16 日（星期五）采用上海证券交易所网络投票系统， 通过交易系统投票平台的投票时间为股东大会召开当日的交易时间段，即 2025 年 5 月 16 日 9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票平台的投 票时间为股东大会召开当日的 9:15-15:00。 二、现场会议地点 浙江省台州市天台县八都工业园区隆兴路 1 号 奥锐特药业公司行政大楼三 楼会议室 目录 | 奥锐特药业股份有限公司 2024 | 年年度股东大会会议议程 1 | | --- | --- | | 奥锐特药业股份有限公司 2024 | 年年度股东大会会议须知 3 | | 议案一：关于公司《2024 | 年年度报告》及其摘要的议案 5 | | 议案二：关于公司 2024 | 年度董事会工作报告的议案 6 ...

Investment Rating - The report indicates a positive outlook for the pharmaceutical raw materials sector, highlighting a significant profit growth in Q1 and an expected improvement in industry supply and demand dynamics [3][4]. Core Insights - The pharmaceutical raw materials sector experienced a revenue of CNY 1176.77 billion in 2024, a year-on-year increase of 6.74%, with a net profit of CNY 150.46 billion, reflecting a growth of 27.89% [3][4][21]. - In Q1 2025, the sector's revenue was CNY 295.46 billion, a slight decline of 0.48% year-on-year, but net profit increased by 20.87% to CNY 45.62 billion [3][4][21]. - The report emphasizes that the rapid profit growth is attributed to several factors, including a low base in H2 2023, the end of inventory destocking by global downstream manufacturers, and improved product pricing stability [3][4][21][23]. Summary by Sections Q1 Performance - The raw materials sector's revenue was stable year-on-year, with a slight decline in Q1 2025 compared to the previous year, while profits showed significant growth [3][4][21]. - The sector's gross margin improved to 38.14% in Q1 2025, up 1.76 percentage points year-on-year, and the net margin reached 15.41%, an increase of 2.63 percentage points [4][25]. Industry Concentration - The top 10 companies in the raw materials sector contributed over 73% of total revenue in 2024, with significant contributions from companies like New and Cheng and Pro Pharmaceutical [31][33]. - In Q1 2025, the top 10 companies accounted for 73.19% of total revenue, indicating a slight decrease in concentration compared to the previous year [33][34]. Valuation and Construction Projects - The report notes that the valuation of the raw materials sector remains at historical lows, with a PE ratio of 30.26x at the end of 2024 and 33.97x at the end of Q1 2025 [5][42]. - The total construction projects in the sector decreased to CNY 163.57 billion by Q1 2025, reflecting a decline of 4.31% year-on-year, indicating a slowdown in capacity expansion [9][44]. Investment Recommendations - The report suggests focusing on companies with strong performance certainty in the formulation and CDMO sectors, such as Aorite and Pro Pharmaceutical, as well as those with significant new product contributions [10][38]. - It highlights the potential for increased demand for raw materials due to the expiration of patents for top-selling small molecule drugs in the coming years [6][42].

证券代码：605116 证券简称：奥锐特 公告编号：2025-036 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 关于为全资子公司提供担保进展情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本次担保情况概述 （一）本次担保基本情况 1、基本情况 | 被担保人名称 | 扬州奥锐特药业有限公司 | | --- | --- | | 统一社会信用代码 | 91321000336432085H | | 成立时间 | 2015-08-05 | | 注册地 | 扬州市高新技术产业开发区健安路 28 号 | | 法定代表人 | 彭志恩 | | 注册资本 | 60,000 万元 | | | 许可项目：药品生产；药品委托生产；药品进出口； | | | 药品批发；药品零售（依法须经批准的项目，经相关 | | | 部门批准后方可开展经营活动，具体经营项目以审批 | | | 结果为准）一般项目：医学研究和试验发展；化工产 | | 主营业务 | 品销售（不含许可类化工产品）；进出口代理；销售代 | ...